Calcium and magnesium use for oxaliplatin-induced neuropathy: A case study to assess how quickly evidence translates into practice

Deirdre R. Pachman, Kathryn J Ruddy, Lindsey R. Sangaralingham, Axel F Grothey, Nilay D Shah, Andreas S Beutler, Joleen M Hubbard, Charles Lawrence Loprinzi

Research output: Contribution to journalArticle

7 Scopus citations


Substantial research efforts have focused on methods of treating and preventing oxaliplatin-associated neuropathy, the doselimiting toxicity associated with this drug. Administration of intravenous calcium and magnesium (CaMg) before and after oxaliplatin has been the most studied approach to preventing oxaliplatininduced neuropathy. Although early reports demonstrated potential benefit, subsequent larger trials failed to confirm the efficacy of CaMg in preventing this adverse effect. This article explores how accumulating evidence for and against the use of CaMg for preventing oxaliplatin-induced neuropathy has impacted clinical practice.

Original languageEnglish (US)
Pages (from-to)1097-1101
Number of pages5
JournalJNCCN Journal of the National Comprehensive Cancer Network
Issue number9
StatePublished - Sep 1 2015


ASJC Scopus subject areas

  • Oncology

Cite this